| Literature DB >> 19761837 |
Isabel Leroux-Roels1, Marie Van der Wielen, Froukje Kafeja, Corinne Vandermeulen, Rajeka Lazarus, Matthew D Snape, Tessa John, Christophe Carre, Nolwenn Nougarede, Stephanie Pepin, Geert Leroux-Roels, Karel Hoppenbrouwers, Andrew J Pollard, Pierre Van Damme.
Abstract
We evaluated the humoral and cellular immunogenicity of adjuvanted and non-adjuvanted H5N1 influenza vaccine in two groups of 300 adults: aged 18-60 and >60 years in a randomized, open-label, uncontrolled phase 2 trial. Participants received two injections (D0, D21) of 7.5 microg hemagglutinin without adjuvant or 30 microg with aluminum hydroxide adjuvant. Antibody responses and cytokine secretion were assessed before and after vaccination. Excluding the 6/300 non-elderly and 47/300 elderly participants with pre-existing antibodies, geometric mean titers (dil(-1)) on D42 were higher with 30 microg+Ad and were comparable between age groups. Participants with pre-existing antibodies responded strongly to the first vaccination (GMTs in the range 147-228 on D21). Vaccination increased both Th1 and Th2 T-cell responses. The predominantly Th1 profile observed before vaccination was unaffected by vaccination. H5N1 influenza vaccine is no less immunogenic in elderly adults than in younger adults and, due to a higher proportion non-naïve elderly, immunogenicity was higher in this latter group.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19761837 DOI： 10.1016/j.vaccine.2009.08.110
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641